This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
Best Momentum Stocks to Buy for July 19th
by Zacks Equity Research
NEOG, OPK and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 19, 2023.
New Strong Buy Stocks for July 19th
by Zacks Equity Research
SOHO, FUTU, NEOG, OPK and THRX have been added to the Zacks Rank #1 (Strong Buy) List on July 19, 2023.
Best Momentum Stocks to Buy for July 12th
by Zacks Equity Research
RMTI, ZUO and OPK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2023.
Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment
by Zacks Equity Research
The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug
by Zacks Equity Research
The FDA approves Pfizer (PFE) and OPKO Health's (OPK) Ngenla to treat growth hormone deficiency in pediatric patients. The drug's commercial launch is expected this August.
Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 71.43% and 26.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
by Zacks Equity Research
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business, and informatics franchise.
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.
Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.
3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Here's Why You Should Hold OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.
OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results reflect dismal segmental performances.
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -10% and 4.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Beats Q2 Earnings Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 23.81% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?